Lower Intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: A meta-analysis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Cai, Rongrong ^a   Yuan, Yang ^a   Zhou, Yi ^a   Xia, Wenqing ^a   Wang, Pin ^a   Sun, Haixia ^a   Yang, Yue ^a   Huang, Rong ^a   Wang, Shaohua ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS; HUMAN; META ANALYSIS; RISK FACTOR;

CHOLESTEROL, LDL; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 84905975868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104922     Document Type: Article

References (40)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
2. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European heart journal 33: 1635-1701.
4. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742.
5. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA: the journal of the American Medical Association 305: 2556-2564.
6. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239. (Pubitemid 38924592)
7. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). The American journal of cardiology 105: 69-76.
8. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, et al. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124: 2458-2473.
9. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, et al. (2011) Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. Journal of the American College of Cardiology 57: 1535-1545.
10. Silva Filho CR, Saconato H, Conterno LO, Marques I, Atallah AN (2005) Assessment of clinical trial quality and its impact on meta-analyses. Revista de saude publica 39: 865-873.
11. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613. (Pubitemid 28380142)
12. Gluud LL, Thorlund K, Gluud C, Woods L, Harris R, et al. (2008) Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of internal medicine 149: 219.
13. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. The New England journal of medicine 355: 549-559. (Pubitemid 44202151)
14. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630. (Pubitemid 35379733)
15. Gissi HFI, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, et al. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1231-1239.
16. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, et al. (1994) Randomized Trial of Cholesterol-Lowering in 4444 Patients with Coronary-Heart-Disease - the Scandinavian Simvastatin Survival Study (4s). Lancet 344: 1383-1389. (Pubitemid 24365311)
17. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA: the journal of the American Medical Association 279: 1615-1622. (Pubitemid 28248586)
18. Officers A, Coordinators for the ACRGTA and Lipid-Lowering Treatment to Prevent Heart Attack T (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA : the journal of the American Medical Association 288: 2998-3007.
19. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, et al. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368: 1155-1163. (Pubitemid 44444932)
20. Group G-PS (2000) Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Italian heart journal: official journal of the Italian Federation of Cardiology 1: 810-820.
21. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine 359: 2195-2207.
22. Collins R, Armitage J, Parish S, Sleigh P, Peto R, et al. (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
23. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158. (Pubitemid 36398384)
24. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, et al. (2007) Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine 357: 2248-2261. (Pubitemid 350190755)
25. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England journal of medicine 333: 1301-1307.
26. Tonkin A, Aylward P, Colquhoun D, Glasziou P, Harris P, et al. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 339: 1349-1357. (Pubitemid 28509344)
27. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. British medical journal 327: 557-560. (Pubitemid 37088507)
28. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. British medical journal 315: 629-634. (Pubitemid 27387172)
29. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44: 720-732.
30. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, et al. (2013) Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. The American journal of cardiology 111: 1123-1130.
31. Preiss D, Sattar N (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Current opinion in lipidology 22: 460-466.
32. Koh KK, Lim S, Sakuma I, Quon MJ (2012) Caveats to aggressive lowering of lipids by specific statins. International journal of cardiology 154: 97-101.
33. Kumar VH, Dwajani S, Gurjar D, Patil U, Vinodkumar C (2011) Effect of rosuvastatin as an anti-inflammatory agent in albino rats. Asian Journal of Pharmaceutical and Clinical Research 4: 74-76.
34. Stancu C, Sima A (2001) Statins: mechanism of action and effects. Journal of cellular and molecular medicine 5: 378-387.
35. Sattar N, Taskinen MR (2012) Statins are diabetogenic-myth or reality? Atherosclerosis Supplements 13: 1-10.
36. Kruit JK, Brunham LR, Verchere CB, Hayden MR (2010) HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Current opinion in lipidology 21: 178-185.
37. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125.
38. Ting RZW, Yang XL, Yu LWL, Luk AOY, Kong APS, et al. (2010) Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovascular diabetology 9.
39. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, et al. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiat 161: 1334-1349. (Pubitemid 38989085)
40. Nakata M, Uto N, Maruyama I, Yada T (1999) Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. Cell Struct Funct 24: 451-455. (Pubitemid 30128952)